Santiago Bonanad

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6410612/publications.pdf

Version: 2024-02-01

79 papers	1,759 citations	394286 19 h-index	302012 39 g-index
83 all docs	83 docs citations	83 times ranked	2290 citing authors

#	Article	IF	Citations
1	Cerebral calcium embolism. Clinical Case Reports (discontinued), 2022, 10, e04962.	0.2	0
2	ABO group-based strategy for inventory management of methylene blue-treated thawed plasma in a blood bank. Transfusion and Apheresis Science, 2022, , 103438.	0.5	0
3	Feasibility, safety and muscle activity during flywheel vs traditional strength training in adult patients with severe haemophilia. Haemophilia, 2021, 27, e102-e109.	1.0	3
4	Ultrasound evaluation of joint damage and disease activity in adult patients with severe haemophilia A using the HEADâ€US system. Haemophilia, 2021, 27, 479-487.	1.0	8
5	Effects of a nonâ€pharmacological approach for chronic pain management in patients with haemophilia: efficacy of cognitiveâ€behavioural therapy associated with physiotherapy. Haemophilia, 2021, 27, e357-e367.	1.0	9
6	Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients. Thrombosis Research, 2021, 205, 99-105.	0.8	4
7	Type 2N VWD: Conclusions from the Spanish PCMâ€EVWâ€ES project. Haemophilia, 2021, 27, 1007-1021.	1.0	0
8	The factor VIII treatment history of nonâ€severe hemophilia A: COMMENT. Joint damage in adult patients with mild or moderate hemophilia A evaluated with the HEADâ€US system. Journal of Thrombosis and Haemostasis, 2021, 19, 2638-2641.	1.9	7
9	Electromyographic and Safety Comparisons of Common Lower Limb Rehabilitation Exercises for People With Hemophilia. Physical Therapy, 2020, 100, 116-126.	1.1	9
10	Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (AdynovateÂ®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. Clinical Pharmacokinetics, 2020, 59, 245-256.	1.6	18
11	Signal transducer and activator of transcription 3 (STAT3) phosphorylation regulates thromboxane A 2 receptor activity in human platelets. British Journal of Haematology, 2020, 188, e39-e42.	1.2	1
12	Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain. BMJ Case Reports, 2020, 13, e234142.	0.2	4
13	Adherence to prophylaxis in adult patients with severe haemophilia A. Haemophilia, 2020, 26, 800-808.	1.0	2
14	Increase of Neutrophil Activation Markers in Venous Thrombosisâ€"Contribution of Circulating Activated Protein C. International Journal of Molecular Sciences, 2020, 21, 5651.	1.8	24
15	Safety and Effectiveness of Progressive Moderate-to-Vigorous Intensity Elastic Resistance Training on Physical Function and Pain in People With Hemophilia. Physical Therapy, 2020, 100, 1632-1644.	1.1	24
16	Unraveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: An Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort. Thrombosis and Haemostasis, 2020, 120, 437-448.	1.8	2
17	Factor XIII deficiency in two Spanish families with a novel variant in gene F13A1 detected by next-generation sequencing; symptoms and clinical management. Journal of Thrombosis and Thrombolysis, 2020, 50, 686-688.	1.0	4
18	Next generation sequencing in bleeding disorders: two novel variants in the F5 gene (Valencia-1 and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 48, 674-678.	1.0	2

#	Article	IF	Citations
19	Identification of 58 Mutations (26 Novel) in 94 of 109 Symptomatic Spanish Probands with Protein C Deficiency. Thrombosis and Haemostasis, 2019, 119, 1409-1418.	1.8	8
20	Clinical and molecular characterization by next generation sequencing of Spanish patients affected by congenital deficiencies of fibrinogen. Thrombosis Research, 2019, 180, 115-117.	0.8	8
21	Physical Activity Monitoring and Acceptance of a Commercial Activity Tracker in Adult Patients with Haemophilia. International Journal of Environmental Research and Public Health, 2019, 16, 3851.	1.2	16
22	Upper-Body Exercises With External Resistance Are Well Tolerated and Enhance Muscle Activity in People With Hemophilia. Physical Therapy, 2019, 99, 411-419.	1.1	11
23	Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 528-541.	1.0	18
24	Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 427-438.	0.8	8
25	Assessment of Kinect V2 for elbow range of motion estimation in people with haemophilia using an angle correction model. Haemophilia, 2019, 25, e165-e173.	1.0	6
26	Crossâ€sectional comparative study of pharmacokinetics and efficacy between sucroseâ€formulated recombinant factor VIII (Kogenate^{Â®}) and BAY 81â€8973 (Kovaltry^{Â®}) in patients with severe or moderate haemophilia A in prophylaxis. Haemophilia, 2019, 25, e215-e218.	1.0	9
27	Predictive factors of immune tolerance treatment response in severe haemophilia A patients with inhibitors: A realâ€world report from a single centre, mixed retrospectiveâ€prospective longâ€term study. Haemophilia, 2019, 25, e97-e100.	1.0	1
28	Joint status in Spanish haemophilia B patients assessed using the Haemophilia Early Arthropathy Detection with Ultrasound (HEADâ€US) score. Haemophilia, 2019, 25, 144-153.	1.0	11
29	Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A. Thrombosis Research, 2019, 174, 151-162.	0.8	27
30	Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA. Haematologica, 2019, 104, 587-598.	1.7	13
31	Î±2-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:Î±2M Levels Are Associated with Venous Thromboembolism. Thrombosis and Haemostasis, 2018, 47, 630-638.	1.8	13
32	Moderate and severe haemophilia in Spain: An epidemiological update. Haemophilia, 2018, 24, e136-e139.	1.0	14
33	Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. Journal of Thrombosis and Haemostasis, 2018, 16, 778-790.	1.9	23
34	Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker. Haemophilia, 2018, 24, e28-e32.	1.0	11
35	GuÃa prÃ¡ctica de tratamiento urgente de la microangiopatÃa trombÃ³tica. Medicina ClÃnica, 2018, 151, 123.e1-123.e9.	0.3	7
36	Timing and severity of inhibitor development in recombinant versus plasmaâ€derived factor VIII concentrates: a SIPPET analysis. Journal of Thrombosis and Haemostasis, 2018, 16, 39-43.	1.9	39

#	Article	IF	Citations
37	HemoKinect: A Microsoft Kinect V2 Based Exergaming Software to Supervise Physical Exercise of Patients with Hemophilia. Sensors, 2018, 18, 2439.	2.1	22
38	Practice guidelines for the emergency treatment of thrombotic microangiopathy. Medicina ClÃnica (English Edition), 2018, 151, 123.e1-123.e9.	0.1	2
39	Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project. PLoS ONE, 2018, 13, e0197876.	1.1	6
40	Pilot evaluation of home delivery programme in haemophilia. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 822-828.	0.7	6
41	Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSSâ€R). American Journal of Hematology, 2017, 92, 614-621.	2.0	12
42	Further psychometric validation of the GAH scale: Responsiveness and effect size. Journal of Geriatric Oncology, 2017, 8, 211-215.	0.5	18
43	Effect of radiosynoviorthesis on the progression of arthropathy and haemarthrosis reduction in haemophilic patients. Haemophilia, 2017, 23, e497-e503.	1.0	12
44	Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients. Haematologica, 2017, 102, 2005-2014.	1.7	35
45	Haemo<scp>PREF</scp>: Further evaluation of patient perception and preference for treatment in a real world setting. Haemophilia, 2017, 23, 884-893.	1.0	7
46	Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective. Haemophilia, 2017, 23, 11-24.	1.0	63
47	Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. International Journal of Molecular Sciences, 2017, 18, 837.	1.8	19
48	<scp>FVIII</scp> inhibitor development according to concentrate: data from the <scp>EUHASS</scp> registry excluding overlap with other studies. Haemophilia, 2016, 22, e36-8.	1.0	11
49	A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. New England Journal of Medicine, 2016, 374, 2054-2064.	13.9	414
50	Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes. Modern Pathology, 2016, 29, 1541-1551.	2.9	11
51	Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes. Journal of Clinical Oncology, 2016, 34, 3284-3292.	0.8	20
52	Molecular and clinical profile of von Willebrand disease in Spain (PCMâ€“EVWâ€“ES): Proposal for a new diagnostic paradigm. Thrombosis and Haemostasis, 2016, 115, 40-50.	1.8	36
53	A simplified assay for the quantification of circulating activated protein C. Clinica Chimica Acta, 2016, 459, 101-104.	0.5	4
54	Platelet function in malignant hematological disorders. Current Opinion in Oncology, 2015, 27, 522-531.	1.1	6

#	Article	IF	Citations
55	Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score. Leukemia Research, 2015, 39, 52-57.	0.4	18
56	Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction. Leukemia Research, 2015, 39, 296-306.	0.4	50
57	Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A. Haemophilia, 2015, 21, 458-464.	1.0	51
58	Quality of thawed plasma inactivated with methylene blue after 48-hour storage. Transfusion and Apheresis Science, 2015, 52, 141-142.	0.5	1
59	Homeâ€delivered ultrasound monitoring for home treatment of haemarthrosis in haemophilia A. Haemophilia, 2015, 21, e147-50.	1.0	16
60	Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale. Journal of Geriatric Oncology, 2015, 6, 353-361.	0.5	51
61	Inhibitor development after switching of <scp>FVIII</scp> concentrate in multitransfused patients with severe haemophilia A. Haemophilia, 2014, 20, 624-629.	1.0	10
62	Novel investigations on the protective role of the <scp>FVIII</scp>/<scp>VWF</scp> complex in inhibitor development. Haemophilia, 2014, 20, 2-16.	1.0	17
63	The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome. Leukemia Research, 2012, 36, 287-292.	0.4	22
64	Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica, 2011, 96, 375-383.	1.7	226
65	Relationships between antithrombin activity, anticoagulant efficacy of heparin therapy and perioperative variables in patients undergoing cardiac surgery requiring cardiopulmonary bypass. Perfusion (United Kingdom), 2011, 26, 487-495.	0.5	16
66	P029 Prognostic relevance of specific chromosomal abnormalities in chronic myelomonocytic leukemia. Leukemia Research, 2009, 33, S74-S75.	0.4	0
67	P030 Prognostic impact on survival of an unsuccessful conventional cytogenetic study in patients with myelodysplastic syndromes (MDS). Leukemia Research, 2009, 33, S75-S76.	0.4	5
68	Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study. International Journal of Clinical Practice, 2006, 60, 518-525.	0.8	24
69	Clotting factors in cryoprecipitate and cryo-supernatant prepared from MB-treated fresh plasma. Transfusion, 2000, 40, 493-493.	0.8	10
70	Influence of Methylene Blue Photoinactivation Treatment on Coagulation Factors from Fresh Frozen Plasma, Cryoprecipitates and Cryosupernatants. Vox Sanguinis, 2000, 79, 156-160.	0.7	43
71	Use of Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) for Carcinoembryonic Antigen, Cytokeratin 19, and Maspin in the Detection of Tumor Cells in Leukapheresis Products from Patients with Breast Cancer: Comparison with Immunocytochemistry. Stem Cells and Development, 1999, 8, 53-61.	1.0	34
72	A New Method for Phenotyping Red Blood Cells Using Microplates. Vox Sanguinis, 1999, 77, 143-148.	0.7	3

#	Article	IF	Citations
73	Prolonged molecular remission after PML/RARÎ±-positive autologous peripheral blood stem cell transplantation in acute promyelocytic leukemia: is relevant pretransplant minimal residual disease in the graft?. Leukemia, 1998, 12, 992-995.	3.3	24
74	Comparison of Two Reverse Transcription-Polymerase Chain Reaction Methods for Detection of AML1/ETO Rearrangement in the M2 Subtype of Acute Myeloid Leukaemia. Clinical Chemistry and Laboratory Medicine, 1998, 36, 137-42.	1.4	1
75	Incidencia de infecciÃ³n por hepatitis C en donantes de cabezas femorales para el banco de tejidos. Revista Espanola De Salud Publica, 1998, 72, 267-271.	0.3	1
76	Minimal illegitimate levels of cytokeratin K19 expression in mononucleated blood cells detected by a reverse transcription PCR method (RT-PCR). Clinica Chimica Acta, 1997, 263, 105-116.	0.5	33
77	HLA-DQA, -DQB AND -DRB ALLELE CONTRIBUTION TO NARCOLEPSY SUSCEPTIBILITY. International Journal of Immunogenetics, 1997, 24, 409-421.	1.2	16
78	CYTOKINES AND PLATELET ACTIVATION IN STORED POOLED BUFFYâ€COATâ€DERIVED PLATELET CONCENTRATES: THE ISSUE OF TRANSFUSIONAL REACTIONS. British Journal of Haematology, 1996, 95, 755-756.	1.2	2
79	Costs of the management of hemophilia A with inhibitors in Spain. Global & Regional Health Technology Assessment, 0, 8, 35-42.	0.2	1